HAIFA, Israel, Aug. 25, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that on August 22, 2011, the U.S. Food and Drug Administration (FDA) designated Pluristem’s PLX cells orphan status for the treatment of thromboangiitis obliterans (Buerger’s disease). The Company also announced that a concurrent application in Europe at the EMA’s Committee for Orphan Medicinal Products is pending.
